These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 2653399)

  • 1. Biological properties of ten human ovarian carcinoma cell lines: calibration in vitro against four platinum complexes.
    Hills CA; Kelland LR; Abel G; Siracky J; Wilson AP; Harrap KR
    Br J Cancer; 1989 Apr; 59(4):527-34. PubMed ID: 2653399
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human ovarian-carcinoma cell lines and companion xenografts: a disease-oriented approach to new platinum anticancer drug discovery.
    Kelland LR; Jones M; Abel G; Valenti M; Gwynne J; Harrap KR
    Cancer Chemother Pharmacol; 1992; 30(1):43-50. PubMed ID: 1586979
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The relationships between glutathione, glutathione-S-transferase and cytotoxicity of platinum drugs and melphalan in eight human ovarian carcinoma cell lines.
    Mistry P; Kelland LR; Abel G; Sidhar S; Harrap KR
    Br J Cancer; 1991 Aug; 64(2):215-20. PubMed ID: 1892748
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative cytotoxicity of CI-973, cisplatin, carboplatin and tetraplatin in human ovarian carcinoma cell lines.
    Perez RP; O'Dwyer PJ; Handel LM; Ozols RF; Hamilton TC
    Int J Cancer; 1991 May; 48(2):265-9. PubMed ID: 2019469
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The establishment, characterization and calibration of human ovarian carcinoma xenografts for the evaluation of novel platinum anticancer drugs.
    Harrap KR; Jones M; Siracky J; Pollard LA; Kelland LR
    Ann Oncol; 1990; 1(1):65-76. PubMed ID: 2078487
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro platinum drug chemosensitivity of human cervical squamous cell carcinoma cell lines with intrinsic and acquired resistance to cisplatin.
    Mellish KJ; Kelland LR; Harrap KR
    Br J Cancer; 1993 Aug; 68(2):240-50. PubMed ID: 8347478
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preclinical antitumor evaluation of bis-acetato-ammine-dichloro-cyclohexylamine platinum(IV): an orally active platinum drug.
    Kelland LR; Abel G; McKeage MJ; Jones M; Goddard PM; Valenti M; Murrer BA; Harrap KR
    Cancer Res; 1993 Jun; 53(11):2581-6. PubMed ID: 8388318
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of cellular accumulation and cytotoxicity of cisplatin with that of tetraplatin and amminedibutyratodichloro(cyclohexylamine)platinum(IV) (JM221) in human ovarian carcinoma cell lines.
    Mistry P; Kelland LR; Loh SY; Abel G; Murrer BA; Harrap KR
    Cancer Res; 1992 Nov; 52(22):6188-93. PubMed ID: 1423261
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acquisition of platinum drug resistance and platinum cross resistance patterns in a panel of human ovarian carcinoma xenografts.
    Jones M; Siracky J; Kelland LR; Harrap KR
    Br J Cancer; 1993 Jan; 67(1):24-9. PubMed ID: 8427780
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytotoxicity of antitumor platinum complexes with L-buthionine-(R,S)-sulfoximine and/or etanidazole in human carcinoma cell lines sensitive and resistant to cisplatin.
    Brooks SE; Korbut TT; Dupuis NP; Holden SA; Teicher BA
    Cancer Chemother Pharmacol; 1995; 36(5):431-8. PubMed ID: 7634385
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Circumvention of acquired tetraplatin resistance in a human ovarian carcinoma cell line by a novel trans platinum complex, JM335 [trans ammine (cyclohexylamine) dichloro dihydroxo platinum (IV)].
    Mellish KJ; Barnard CF; Kelland LR; Harrap KR
    Int J Cancer; 1994 Oct; 59(1):65-70. PubMed ID: 7927906
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel trans platinum complexes: comparative in vitro and in vivo activity against platinum-sensitive and resistant murine tumours.
    Goddard PM; Orr RM; Valenti MR; Barnard CF; Murrer BA; Kelland LR; Harrap KR
    Anticancer Res; 1996; 16(1):33-8. PubMed ID: 8615631
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro cytotoxicity, protein binding, red blood cell partitioning, and biotransformation of oxaliplatin.
    Pendyala L; Creaven PJ
    Cancer Res; 1993 Dec; 53(24):5970-6. PubMed ID: 8261411
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preclinical activity of a new platinum analogue, lobaplatin, in cisplatin-sensitive and -resistant human testicular, ovarian, and gastric carcinoma cell lines.
    Harstrick A; Bokemeyer C; Scharnofkse M; Hapke G; Reile D; Schmoll HJ
    Cancer Chemother Pharmacol; 1993; 33(1):43-7. PubMed ID: 8269588
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro interactions between platinum analogues in human ovarian-carcinoma cell lines.
    Perez RP; Perez KM; Handel LM; Hamilton TC
    Cancer Chemother Pharmacol; 1992; 29(6):430-4. PubMed ID: 1568285
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen panel.
    Rixe O; Ortuzar W; Alvarez M; Parker R; Reed E; Paull K; Fojo T
    Biochem Pharmacol; 1996 Dec; 52(12):1855-65. PubMed ID: 8951344
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanism-related circumvention of acquired cis-diamminedichloroplatinum(II) resistance using two pairs of human ovarian carcinoma cell lines by ammine/amine platinum(IV) dicarboxylates.
    Kelland LR; Mistry P; Abel G; Loh SY; O'Neill CF; Murrer BA; Harrap KR
    Cancer Res; 1992 Jul; 52(14):3857-64. PubMed ID: 1617660
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative activity and distribution studies of five platinum analogues in nude mice bearing human ovarian carcinoma xenografts.
    Boven E; van der Vijgh WJ; Nauta MM; Schlüper HM; Pinedo HM
    Cancer Res; 1985 Jan; 45(1):86-90. PubMed ID: 4038381
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sensitivity to novel platinum compounds of panels of human lung cancer cell lines with acquired and inherent resistance to cisplatin.
    Twentyman PR; Wright KA; Mistry P; Kelland LR; Murrer BA
    Cancer Res; 1992 Oct; 52(20):5674-80. PubMed ID: 1327513
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selective potentiation of platinum drug cytotoxicity in cisplatin-sensitive and -resistant human ovarian carcinoma cell lines by amphotericin B.
    Sharp SY; Mistry P; Valenti MR; Bryant AP; Kelland LR
    Cancer Chemother Pharmacol; 1994; 35(2):137-43. PubMed ID: 7987990
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.